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infarcted myocardium, as was first proposed in Chugh’s hypothesis
(6).
An important relevant observation is that the study population
had a mean duration of occlusion of the CTO vessel of 12  20
months. This study is therefore more likely to be able to answer the
often asked question about the role of angiographic collaterals in
predicting myocardial viability. This is because it is believed that
CTOs such as these give adequate time for collateral development,
unlike the recent occlusions studied using contrast echocardiogra-
phy soon after acute MI (7).
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REPLY
Dr. Chugh’s comments regarding our chronic total occlusion
(CTO) experience are well stated and germane to our findings.
Our intent for this project was to investigate the association
between long-term survival and successful recannulization of a
CTO. In order to demonstrate this association, a matched cohort
was developed using a propensity-scoring model. Thus, the com-
parison groups were remarkably similar with respect to baseline
covariates that are known predictors of long-term survival. In fact,
the survival curves for the matched cohort and the CTO group
were markedly similar. Only those patients with a successful
recannulization of a CTO demonstrated a survival benefit. This
link persisted following multivariate adjustment and was identified
in the failed percutaneous coronary intervention (PCI) cohort in
whom successful surgical recannulization of the CTO was per-
formed.
In our opinion, this body of work clearly identifies a group of
patients in whom successful PCI is associated with improved
long-term survival. There is no question that further work needs to
be performed on the mechanism of survival. Two leading theories
are certainly collateral flow and viability. Other plausible explana-
tions that are worthy of future investigation include the effect of
successful recannulization upon the incidence of sudden cardiac
death, left ventricular remodeling, and identification of certain
clinical patient subsets that are associated with an improved
survival following CTO and recannulization. For example, patients
with a history of diabetes mellitus have been demonstrated to have
a decreased incidence of collateral vessel formation despite abnor-
mal coronary atherosclerosis. However, patients with a history of
diabetes mellitus derived substantial benefit from a successful
recannulization of a chronic total occlusion in our study (data not
shown). To further our understanding of this cohort, we have
identified 558 patients from our nuclear database with a peri-
procedural radionucleotide perfusion study. We are hopeful that
this additional information will result in an enhanced understand-
ing of the survival benefit of successful recanalization of a CTO.
Finally, Dr. Chugh’s comments are insightful and, it is hoped,
will prompt future investigation into the mechanism of survival
benefit associated with a successful recannulization of a CTO.
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Is a High Hematocrit Level
Good for Patients With Heart Failure?
We were interested to read the article by Al-Ahmad and colleagues
(1) regarding the prognostic value of impaired renal function and
anemia in patients with left ventricular (LV) dysfunction, pub-
lished in the Journal of the American College of Cardiology. The
investigators report that reduced kidney function and a low
hematocrit are independent risk factors for increased all-cause
mortality in patients with LV dysfunction, with there being a
synergistic relationship between the two parameters. The results
from this study, together with other work in the field (2), may have
important clinical implications for the management of patients
with chronic heart failure (CHF). However, we believe several
points deserve further consideration.
The prognostic benefits of treating anemia in CHF and whether
there is an optimal range of hematocrit for survival are not known.
In the Framingham study, the impact of hematocrit on all-cause
death as well as morbidity and mortality due to cardiovascular
disease was shown to follow a U-shaped curve (3). Other prospec-
tive epidemiological studies of healthy populations have shown
that the lowest mortality rate correlates with a mid-range hemat-
ocrit level in both genders and at all ages (4). Al-Ahmad et al. (1)
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assessed survival in patients subdivided according to hematocrit
values 35%, 35% to 39%, and 40%. It is not clear why the
investigators grouped all patients with a hematocrit value of 40%
(n  5,128, 77%) into one category. According to data from
Europe and North America, the normal range of hematocrit for
males is 40% to 53% and that of females 36% to 48% (5). Therefore,
it would have been more appropriate to further subdivide patients
with a hematocrit above 40%, enabling the impact of polycythemia on
survival to be assessed. Heart failure is a procoagulant state, even for
patients in sinus rhythm, and hence polycythemic patients are likely to
be at particular risk of thrombotic events and would be expected to
have a higher mortality.
In vitro studies have shown that angiotensin-converting enzyme
inhibitors can lower hematocrit levels via the inhibition of eryth-
ropoietin synthesis. It would have been interesting to have assessed
whether enalapril treatment resulted in a clinically significant
change in hematocrit over time. Although Al-Ahmad et al.
excluded patients with severe pulmonary disease from their study,
whether patients with coexisting chronic obstructive pulmonary
disease (COPD) were also excluded is not reported. This may be
an important confounding factor as COPD is a well-recognized
cause of secondary polycythemia.
The study by Al-Ahmad and colleagues (1) mostly investigated
male (86%) and asymptomatic (62%) patients. The use of eryth-
ropoietin for the treatment of anemia in CHF is likely to benefit
only symptomatic patients, particularly those with more advanced
heart failure. Although the findings of Al-Ahmad et al. are clearly
of significance, further studies are required to establish which
patients should be targeted for erythropoietin therapy and whether
there is an optimal range of hematocrit (or hemoglobin) for which
one should aim.
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Dr. Sharma and colleagues raise the question of a U-shaped
relationship between hematocrit and all-cause mortality. We
explored the possibility of a nonlinear relationship between hemat-
ocrit and survival time by including a quadratic hematocrit term in
the Cox regression (1). The term was not significant, which
allowed us to rule out a simple U relationship. We did not present
analyses of all-cause mortality itself because follow-up times were
quite variable and much of the data was censored. However, as an
example of these results, in our data those male patients with
hematocrit from 40% to 49% (n  4,235) had 22% mortality,
whereas those male patients with hematocrit of 50 or higher (n 
344) had a mortality of 23%, not a statistically significant difference
(p  0.47). We concluded that a nonlinear model did not fit the
data any better than did a linear model.
Sharma and colleagues also question our subdivision of the
population into hematocrit values 35, 35 to 39, and 40%. The
division into subgroups was performed both to describe the
prevalence of risk factors as hematocrit declines into the anemic range
and to provide a graphic representation of the effect of a decline in
hematocrit into the anemic range using univariate Kaplan-Meier
analyses. In the multivariable Cox proportional hazards model, how-
ever, hematocrit was evaluated as a continuous variable.
We agree that additional randomized controlled trials are
needed to assess the efficacy, safety, and potential target hematocrit
(hemoglobin) goals in patients with heart failure. Silverberg et al.
(2) did not note any adverse side effects in patients with advanced
heart failure who were randomized to a treatment hemoglobin goal
of at least 12.5 g/dl compared with the placebo arm of 10 to
11.5 g/dl. However, a recent randomized controlled trial in the
hemodialysis population, in patients with a history of heart failure
or ischemic heart disease, showed a trend toward worse outcomes
in those patients whose goal hematocrit was 42% compared with
those whose goal was 30% (3). Admittedly, dialysis patients are
distinct from heart failure patients in the general population;
however, caution should be exercised when choosing the higher
hematocrit target in clinical trials of patients with heart failure.
Sharma et al. make the point that in vitro studies show that
angiotensin-converting enzyme inhibitors (ACE-I) may lower the
hematocrit. In fact, human studies using ACE-I have shown
similar results (4,5). Analyses of follow-up of hematocrit levels may
have been insightful, but we believed this was beyond the scope
and goal of the current study.
Finally, Sharma and co-workers are of the opinion that treat-
ment of anemia is likely to benefit only symptomatic patients.
Although this may be true, we believe this conclusion is premature. In
fact, although we did not show the analyses in our report, the hazard
ratio for every decrease in unit hematocrit was similar in the asymp-
tomatic prevention and the symptomatic treatment trials of the
Studies of Left Ventricular Dysfunction, implying that treatment of
anemia could theoretically be useful even in asymptomatic patients.
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